Treatment of TNNT1-Myopathy With L-Tyrosine.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02035501|
Recruitment Status : Unknown
Verified January 2014 by Shimon Edverson, Hadassah Medical Organization.
Recruitment status was: Enrolling by invitation
First Posted : January 14, 2014
Last Update Posted : January 14, 2014
|Condition or disease||Intervention/treatment||Phase|
|Nemaline Myopathy||Drug: L-Tyrosine Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||January 2015|
|Active Comparator: L-Tyrosine||Drug: L-Tyrosine|
|Placebo Comparator: Placebo||Drug: Placebo|
- 1. goal attainment score [ Time Frame: 3 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02035501
|Hadassah Medical Organization, Jerusalem, Israel|